SK Bioscience

SK Bioscience

SK Bioscience is a subsidiary of South Korean conglomerate SK Group and focuses on the discovery and production of vaccines. It was established in 2018 and is located in Seongnam, South Korean.

All edits

Edits on 18 Apr, 2020
Jessica Karpinski
Jessica Karpinski edited on 18 Apr, 2020
Edits made to:
Description (+69 characters)
Article (+274/-4 characters)
Further reading (+2 rows) (+10 cells) (+328 characters)
Categories (+1 topics)
Topic thumbnail

SK Bioscience

SK Bioscience is a subsidiary of South Korean conglomerate SK Group and focuses on the discovery and production of vaccines. It was established in 2018 and is located in Seongnam, South Korean.

Article

SK Bioscience is a subsidiary of South Korean conglomerate SK Group and focuses on the discovery and production of vaccines. The vaccine research and production company was spun out from SK Chemicals in 20152018.

...
COVID-19

The company researched and developed a medical solution for COVID-19 using a monoclonal antibody treatment candidate. The company has a manufacturing plant that can produce vaccines for the virus once they have been approved by the appropriate governing bodies.

Further reading

Title
Author
Link
Type
Date

SK Bioscience starts animal trial of COVID-19 vaccine - Korea Biomedical Review

Lee Han-soo

Web

March 23, 2020

SK Bioscience to expand vaccine production facility - Korea Biomedical Review

Marian Chu

Web

July 18, 2018

Categories
Edits on 8 Apr, 2020
Jason D. Rowley
Jason D. Rowley approved a suggestion from Golden's AI on 8 Apr, 2020
Edits made to:
Article (+30/-30 characters)
Article

In 2006, SK Bioscience began research for a self-developed vaccine. In 2014, the company signed an agreement with Sanofi Pasteur SA for joint R&D and the sale of next-generation’s pneumococcal conjugate vaccinepneumococcal conjugate vaccine (PCV).

Jason D. Rowley
Jason D. Rowley edited on 8 Apr, 2020
Edits made to:
Infobox (+8/--1 properties)
Timeline (+15 events) (+1075 characters)
Description (+124 characters)
Article (+1158 characters)
Categories (+1 topics)
Topic thumbnail

SK Bioscience

SK Bioscience is a subsidiary of South Korean conglomerate SK Group and focuses on the discovery and production of vaccines.

Article

SK Bioscience is a subsidiary of South Korean conglomerate SK Group and focuses on the discovery and production of vaccines. The vaccine research and production company was spun out from SK Chemicals in 2015.

Technology

SK Bioscience has technology capabilities in R&D and manufacturing.

Its research and development technologies include suspension cell culture, conjugation technology, and reverse genetic technologies. Its main production facility L HOUSE, located in Andong Gyeongbuk Bio Industrial Complex, uses single-use bags in its bioreactor, rather than conventional stainless steel tanks.

Research History

In 2006, SK Bioscience began research for a self-developed vaccine. In 2014, the company signed an agreement with Sanofi Pasteur SA for joint R&D and the sale of next-generation’s pneumococcal conjugate vaccine (PCV).

It also developed other vaccine products, including Korea’s first cell culture-derived trivalent influenza vaccine (2014) and the world’s first cell culture-derived quadrivalent influenza vaccine (2015).

...

It has acquired marketing approval for “SKYZOSTER”, a shingles vaccine (2017), and SKY Varicella, a varicella vaccine (2018).

Infobox
Company status
Active
Email address
skpharma@sk.com
Fax number
+82 - 2 - 2008 - 7899
Full address
310 Pangyo-ro, Bundang-gu, Seongnam-si, Gyeonggi-do (13494)
Industry
Contract research organization
Location
Seongnam
Phone number
+82-2-2008-2200
Place of incorporation
South Korea
Categories
Timeline

March 23, 2020

SK Bioscience starts animal trial of COVID-19 vaccine

2018

Established SK Bioscience

2017

Signed an agreement with international organization PATH to develop and produce pediatric enteritis vaccine for developing countries

2017

Launched Sky Zoster Inj., world’s second shingles vaccine

2017

Gained approval for SKYPNEUMO, the first domestically produced PCV13 vaccine

2016

Launched SKYCellflu, Korea’s first trivalent cell culture-derived influenza vaccine

2016

Launched SKYCellflu Quadrivalent, world’s first quadrivalent cell culture-derived influenza vaccine

2015

Acquired KGMP for L HOUSE (Andong Vaccine Plant)

2014

Established strategic partnership with Sanofi Pasteur for co-development of next-generation’s pneumococcal conjugate vaccine

2013

Established partnership with IVI (International Vaccine Institute) to collaborate on the development of a new typhoid conjugate vaccine

2012

Construction of L HOUSE (Andong Vaccine Plant) completed

2009

Out-licensed CSL’s NBP601 (hemophilia drug), Korea’s first bio-pharmaceutical drug

2006

Merged with Dongshin Pharm

2005

Established Vaccine R&D Center

2001

Acquired Dongshin Pharm (vaccine, blood products)
Jason D. Rowley
Jason D. Rowley edited on 8 Apr, 2020
Edits made to:
Infobox (+1 properties)
Infobox
Location
South Korea
Jason D. Rowley"Initial creation data"
Jason D. Rowley edited on 8 Apr, 2020
Edits made to:
Infobox (+2 properties)
Infobox
Is a
Company
Jason D. Rowley"Created via: Web app"
Jason D. Rowley created this topic on 8 Apr, 2020
Edits made to:
Topic thumbnail

 SK Bioscience

SK Bioscience is a subsidiary of South Korean conglomerate SK Group and focuses on the discovery and production of vaccines. It was established in 2018 and is located in Seongnam, South Korean.

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.